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1. Introduction  
Ovarian cancer is one of the most lethal gynecological cancers in the United States. NCI 
estimates ~21,880 new cases with ~13,850 deaths in 2011 (http://www.cancer.gov/ 
cancertopics/ types/ovariancancer). Unfortunately, the majority of these cases are only 
discovered at advanced stages (stage III or IV) due to the cancer’s asymptomatic nature which 
has an overall survival rate between 5-25% (Bast et al., 2009; Hennessy et al., 2008). Hence, the 
inability to detect this disease during early stages has led to poor prognosis. Despite 
improvements in medicine and patient care, reasonable screening measures for detecting early 
stage ovarian cancers are presently lacking. Thus, a better understanding of the molecular 
events that underlie ovarian cancer development are needed.  
The current strategy for treatment of ovarian cancer is surgical debulking followed by 
chemotherapy (Bast et al., 2009; Hennessy et al., 2008). Although ~70% of ovarian cancers 
respond to a combination of platinum and taxane-based chemotherapy administered after 
surgery, current treatments are of limited efficacy in preventing tumor recurrence and 
progression (Bast et al., 2009; Hennessy et al., 2008). Thus, new anti-neoplastic agents are 
urgently needed to increase the chemotherapeutic sensitivity of ovarian cancer cells.  
Recently, evidence has emerged revealing the importance of genomic aberrations in the 
progression of ovarian cancer (Gorringe & Campbell, 2009; Gray et al., 2003). Through the 
use of high throughput technologies (i.e. array comparative genomic hybridization (aCGH), 
microarray, and SNP arrays), specific genomic regions have been identified to be either 
amplified or silenced in tumor progression (Gorringe & Campbell, 2009; Gray et al., 2003). 
One such region which we and others (Nanjundan et al., 2007; Osterberg et al., 2009) have 
previously identified to be frequently amplified early in serous epithelial ovarian cancer 
development is the 3q26.2 region which harbors Transforming Growth Factor  pathway 
(TGF) co-repressors, ecotropic viral integration site-1 (EVI1) (Nanjundan et al., 2007) and 
SnoN/SkiL (Nanjundan et al., 2008). A large amount of work has recently emerged 
involving the intricacies of TGF signaling and its role in cancer progression. Importantly, 
this signaling pathway is dysregulated in ovarian carcinomas.  
2. Dual functionality of TGFsignaling in cancer 
There exist three isoforms of TGF, namely TGF1, TGF2, and TGF3, which are initially 
present in the inactive latent form (L-TGF) (Elliott & Blobe, 2005; Meulmeester & Ten Dijke, 
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2011). In its active dimeric form, the TGF ligand binds to the TGF receptor type II (TGFRII) 
leading to heterotetrameric receptor complex formation with TGFRI. In addition, the co-
receptor, TGFRIII or proteoglycan (a.k.a. endoglin), aids binding of the ligand to the TGFRII 
(Elliott & Blobe, 2005; Meulmeester & Ten Dijke, 2011). The activated receptors then recruit 
receptor regulated SMADs (R-SMADs) such as SMAD2/3 which form a complex with a Co-
SMAD, SMAD4, and then shuttles into the nucleus. These activated SMADs associate with 
DNA binding transcription factors to enhance DNA binding to regulate transcription of TGFβ 
target genes such as cyclin-dependent kinase inhibitors (i.e. p21, involved in regulating cell 
survival) (Elliott & Blobe, 2005) (Figure 1).  The TGF pathway is regulated via several 
mechanisms including (1) phosphorylation, (2) ubiquitination, (3) inhibitory SMADs (i.e. 
SMAD6 and SMAD7), and (4) transcriptional co-repressors (i.e. SnoN/SkiL and EVI1) (Elliott 
& Blobe, 2005; Meulmeester & Ten Dijke, 2011). In addition to the canonical SMAD dependent 
pathway, there exists the non-canonical pathway involving (1) TRAF5/TAK1/p38-JNK, (2) 
RhoA/ROCK, and (3) ERK/MAPK (Elliott & Blobe, 2005; Meulmeester & Ten Dijke, 2011).  
 
 
Fig. 1. The TGF signaling pathway. Active dimeric TGF ligand binds to TGFRII on the 
cell surface leading to complex formation with TGFRI. Endoglin (TGFRIII) assists in 
recruitment of the active TGF ligand to bind to the cell surface receptors. Following 
receptor activation, receptor SMADs (SMAD2/3) become phosphorylated and form a 
complex with the Co-SMAD (SMAD4) which then translocate into the nuclear compartment 
to regulate transcription of various TGF target genes. 
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The TGF signaling pathway has the ability to transition from a tumor suppressor (in 
normal or early stage cancers) to a tumor promoter (late stages of cancer) (Elliott & Blobe, 
2005; Meulmeester & Ten Dijke, 2011) (Figure 2). During the early stages of epithelial 
tumorigenesis, TGFβ inhibits tumor development and growth by inducing cell cycle arrest, 
senescence, and apoptosis; this aids in maintaining cellular homeostasis critical for 
prevention of continuous cell proliferation and thus tumor formation (Elliott & Blobe, 2005). 
This functionality is elicited via induction of cyclin-dependent kinase inhibitors (CDK), 
namely p15, p21, and p27. TGF also represses expression of the c-myc oncogene which 
leads to activation of these CDK inhibitors (Elliott & Blobe, 2005; Meulmeester & Ten Dijke, 
2011). Additional molecules that are involved in the TGF apoptotic functional response 
include the death receptor FAS, GADD45b, BIM, and DAPK (Elliott & Blobe, 2005; 
Meulmeester & Ten Dijke, 2011).  
 
 
 
 
Fig. 2. The TGF signaling pathway elicits dual functionality. The pathway can transition 
from a tumor suppressive (normal or early stages of cancer) role to a tumor promoting role 
(late stages of cancer).   
During the progression of cancer, mutations in these components may lead to disruption 
of TGF mediated control of cell proliferation. In late stages of tumor progression, tumor 
cells become resistant to growth inhibition due to inactivation of the TGFβ signaling 
pathway thus leading to altered cell cycle control (Elliott & Blobe, 2005). TGF becomes 
capable of inducing metastatic functions via increased cellular migration, invasiveness, 
loss of epithelial markers, and a corresponding acquisition of mesenchymal 
characteristics.  
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3. Dysregulated TGFsignaling in ovarian cancer 
Several components of the TGFsignaling pathway have been reported to be dysregulated 
in ovarian cancers and are summarized in the subsections below.  
3.1 TGFligand expression in ovarian cancer 
By immunohistochemical and in situ hybridization approaches, all of the three TGF 
ligands (TGF1, TGF2, and TGF3) are markedly elevated in ovarian cancer cells 
(Henriksen et al., 1995). Similar results were obtained via RNAse protection assay in 
primary ovarian cancer specimens (Bartlett et al., 1997). Northern blot analysis indicated 
that mRNA levels of both TGF1 and TGF3 are increased in recurrent ovarian cancers 
(Bristow et al., 1999). Using enzyme-linked immunosorbant assay (ELISA), TGF1 levels 
are increased in plasma and peritoneal fluid of advanced stage ovarian cancer patients 
(Santin et al., 2001). Increased expression of TGF appears to be correlated with a poor 
patient survival outcome which is associated with peritoneal metastasis, expression of 
vascular endothelial growth factor (VEGF), and microvessel density (markers of 
angiogenesis) (Nakanishi et al., 1997).  
Mutational analysis of TGF1 assessed by PCR-SSCP (polymerase chain reaction single-
strand conformational polymorphism) uncovered defects in the coding region of exons 5, 6, 
and 7 (Cardillo et al., 1997). However, these alterations were not associated with histological 
type of the tumor or its transcript/protein expression levels (Cardillo et al., 1997). 
3.2 TGFreceptor expression in ovarian cancer 
There appears to be some discrepancy in the reported levels of TGF receptors in ovarian 
cancer which may be due to the nature of the cell lines and tumor specimens assessed. In 
one study, the proximal components of the TGF signaling pathway (receptor expression 
and its phosphorylation status) appeared to be intact in primary ovarian cancer cell cultures; 
this indicated that downstream mechanisms could be responsible for growth resistance to 
TGF such as increased matrix metalloproteinase-2 (MMP2) expression (Yamada et al., 
1999). Yet in another report, TGFRII transcripts were undetectable in TGF resistant 
ovarian cancer cell lines (AZ224 and AZ547) whereas SKOV3 cells were positive for 
TGFRII expression (Zeinoun et al., 1999).  TGFRII was also detectable in an additional 14 
ovarian cancer cell lines (Hu et al., 2000) (Xi et al., 2004). A more recent study reported 
reduced TGFRII levels which was determined via microarray analysis and validated via 
real-time PCR (qPCR) (Sunde et al., 2006).  
Via northern blot analysis, expression of TGFRI and TGFRIII was markedly reduced in 
recurrent ovarian tumors (Bristow et al., 1999). In an independent study, TGFRIII was 
notably decreased or absent in ovarian cancers at the RNA and protein levels (Hempel et al., 
2007).  
Mutational analysis of TGFRI and TGFRII uncovered mutations in a minority of ovarian 
cancers (Ding et al., 2005). Specifically, a frameshift mutation has been identified in Exon 5 
of TGFRI in 31% of ovarian tumors (Wang et al., 2000b), in exons 2, 3, 4, and 6 of TGFRI 
(catalytic domain of the kinase) in 33% primary ovarian cancers (Chen et al., 2001), and 
deletions in exon 1 of  TGFRI in <30% of ovarian tumors (Antony et al., 2010). Likewise, 
missense mutations have been identified in TGFRII (Francis-Thickpenny et al., 2001) and 
deletions in exon 3 of TGFRII in ovarian tumors (Antony et al., 2010). 
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3.3 SMAD expression in ovarian cancer 
Decreased expression of SMAD4 has been described in several ovarian cancer cell lines (Hu 
et al., 2000) which appears to correlate with dysregulated expression of p21 and c-myc  
(Antony et al., 2010).  
Unlike pancreatic cancer in which ~50% of SMAD4 is mutated (Elliott & Blobe, 2005), 
reports of the presence of SMAD4 variants in ovarian cancers are lacking (Wang et al., 
2000b). However, mutational analysis of additional SMAD family members showed that 
35% and 23%, respectively, of ovarian tumor specimens contained a polymorphism in intron 
2 of SMAD6 and a polymorphism at codon 208 in SMAD7. Neither of these mutations were 
associated with amino acid changes and thus, are unlikely to be important in ovarian cancer 
development (Wang et al., 2000a). Similarly, 42% of ovarian tumor specimens had a 
polymorphism for SMAD2 which was not associated with an amino acid change; thus it is 
also unlikely that this mutation is significant in the development of ovarian cancer (Wang et 
al., 1999).  
3.4 TGFtranscriptional co-regulator/co-factor expression in ovarian cancer 
Ecotropic viral integration site-1 (EVI1), a TGF corepressor, was elevated up to 40-fold in 
ovarian carcinoma cells via RNAse protection assay (Brooks et al., 1996).  Similarly, via 
microarray analysis and qPCR validation, EVI1 was found to be upregulated in advanced 
stage ovarian cancers (Sunde et al., 2006). In our analysis, we identified that EVI1 and 
MDS1/EVI1 are amplified in advanced stage serous epithelial ovarian cancers at the DNA, 
RNA, and protein levels via aCGH, transcriptional profiling/qPCR analysis, and western 
blot analysis (Nanjundan et al., 2007). Further, SnoN/SkiL, another TGF corepressor, is 
likewise increased at the DNA and RNA levels (cCGH and qPCR) in advanced stage serous 
epithelial ovarian cancers (Nanjundan et al., 2008). In addition, c-myc, an oncogenic 
transcriptional regulator, is upregulated in ovarian cancers (Garte, 1993).  
3.5 Other TGFmediator expression in ovarian cancer 
Other TGF mediators whose expression is altered in ovarian cancers include DACH1 and 
BMP7 which are both upregulated and inhibit TGF signaling (Sunde et al., 2006). 
Mediators in ovarian cancers that are downregulated include PCAF and TFE3 (which 
enhance TGF  signaling) (Sunde et al., 2006). Other molecules that could attenuate 
TGFproliferative control include FOXG1 which is overexpressed in high-grade ovarian 
cancers and suppresses p21 WAF1/CIP1 transcription (Chan et al., 2009). BAMBI (BMP and 
activin membrane-bound inhibitor) is overexpressed in ovarian cancers promoting 
resistance to TGF mediated apoptosis by shuttling into the nuclear compartment with 
SMAD2/3 in a TGF dependent manner (Pils et al., 2011). EZH2 is increased in ovarian 
cancers and appears to be involved in altering metastatic potential by upregulating TGF1 
(Rao et al., 2010).  A SMAD4 target gene, RunX1T1, is a tumor suppressor in ovarian cancers 
and is repressed by histone modifications (Yeh et al., 2011).  
4. SnoN/SkiL, a TGFtranscriptional modulator, in ovarian cancer 
SnoN/SkiL belongs to the Ski family (i.e. Ski, SnoN, Fussel-15, and Fussel-18), a group of 
proto-oncogenes involved in early developmental processes sharing structural and 
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functional features characteristic of winged-helix/forkhead class of DNA binding proteins 
(Deheuninck & Luo, 2009). However, these proteins do not directly bind to DNA but 
associate to DNA via interaction via nuclear proteins (i.e. SMADs) (Deheuninck & Luo, 
2009). Thus, the mechanism of repression of TGF signaling occurs by transcriptional 
modulation by recruitment of nuclear corepressors (i.e. N-CoR), histone deacetylase 
complex (HDAC), and interference of SMAD-mediated binding to the transcriptional 
coactivator, p300/CBP (Deheuninck & Luo, 2009). Ski and SnoN genes have an overall 
homology of 50% and both are tightly regulated at multiple levels via: (1) transcriptional 
regulation, (2) protein degradation, (3) post-translational modifications, and (4) subcellular 
localization (Deheuninck & Luo, 2009; Luo, 2004; Pan et al., 2009). SnoN is not only 
phosphorylated by TGF activating kinase (TAK1) but can also physically associate with 
TAK1 leading to SnoN degradation (Kajino et al., 2007). SnoN is degraded rapidly via 
proteasome-mediated degradation upon TGF stimulation via SMURF2, APC, and Arkadia 
(RNF111) E3 ubiquitin ligases (Inoue & Imamura, 2008; Izzi & Attisano, 2004; Levy et al., 
2007). SnoN can also interact with promyelocytic leukemia protein (PML) which promotes 
its association with PML nuclear bodies to stabilize p53 leading to induction of premature 
senescence (Lamouille & Derynck, 2009; Pan et al., 2009). SnoN can be sumoylated via 
SUMO E3 ligase PIAS independently of TGF signaling and its ubiquitination status (Hsu et 
al., 2006; Wrighton et al., 2007). Although sumoylation does not alter its stability or 
subcellular localization, it may augment SnoN-mediated repression of TGF signaling on 
specific promoters such as the myogenin promoter (Hsu et al., 2006). Although SnoN is 
predominantly nuclear localized, it can be cytoplasmically localized in normal cells under 
non-pathological conditions (Krakowski et al., 2005).  
Both Ski and SnoN are expressed in all adult tissues at low levels and are involved in 
differentiation of neural and muscle cells (Deheuninck & Luo, 2009; Luo, 2004; Pan et al., 
2009). Expression of Ski and SnoN are altered in numerous disease states including cancer 
(Deheuninck & Luo, 2009; Luo, 2004; Pan et al., 2009). Our research indicates that SnoN 
levels are upregulated in serous epithelial ovarian cancers via different mechanisms 
including gene amplification, altered protein stability, and transcriptional activation 
(Nanjundan et al., 2008). Further, siRNA targeting SnoN leads to reduction in ovarian cancer 
cell proliferation implicating a pro-oncogenic function (Nanjundan et al., 2008; Smith et al., 
2010). In addition, attenuated SnoN protein via siRNA is detrimental to breast and lung 
cancer cellular transformation in both in vitro and in vivo mouse xenograft models (Zhu et 
al., 2007). Strikingly, SnoN has also been implicated in a tumor suppressive function. 
Deletion of one copy of SnoN leads to increased susceptibility to carcinogen-induced tumor 
development (Deheuninck & Luo, 2009; Luo, 2004; Pan et al., 2009). Furthermore, long-term 
stable expression of SnoN in an ovarian cell line leads to induction of senescence (i.e. 
oncogene-induced senescence similar to that described for Ras) (Nanjundan et al., 2008). In 
another study, SnoN induces premature senescence in a PML and p53–dependent fashion; it 
also inhibits epithelial-mesenchymal transition (EMT) and tumor metastasis in breast and 
lung cancer cells (Pan et al., 2009; Zhu et al., 2007). Collectively, these findings suggest that 
SnoN elicits multiple roles in cancer development.  
5. EVI1, a TGFtranscriptional modulator, in ovarian cancer 
EVI1, ecotropic viral integration site-1 protein, now called MECOM (MDS1 and EVI1 
complex) is located at the 3q26.2 locus. It was initially identified as a site for viral integration 
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in mouse cancer models; it has been well studied as an oncogene in acute myeloid leukemia 
(AML) and in myelodysplastic syndrome (MDS) (Levy et al., 1994; Morishita et al., 1992b). 
Functions of EVI1 include (1) proliferation of leukemic cells (Tanaka et al., 1995), (2) cellular 
transformation (Kilbey & Bartholomew, 1998), (3) inhibition of growth factor mediated 
differentiation and survival (Morishita et al., 1992a), (4) induction of neural and 
megakaryocyte differentiation, and (5) inhibition of interferon (Buonamici et al., 2005) and 
TGF signaling (Izutsu et al., 2001; Soderholm et al., 1997; Sood et al., 1999; Vinatzer et al., 
2003; Vinatzer et al., 2001). Notably, EVI1 represses transcription via binding to SMADs and 
recruiting CtBP1/HDAC (Izutsu et al., 2001; Palmer et al., 2001; Senyuk et al., 2002) to target 
promoter elements, increasing AP-1 activity (Tanaka et al., 1994), disrupting JNK induced 
apoptosis (Maki et al., 2008), inhibiting PML function (Buonamici et al., 2005), binding to 
BRG1 (Chi et al., 2003), and activating PI3K by reducing TGF and drug induced apoptosis 
(Liu et al., 2006; Yoshimi et al., 2011). Supporting its role as an inducer of cellular 
proliferation, EVI1 knockout mice are embryonically lethal due to hypocellularity across 
multiple organ sites (Hoyt et al., 1997). There exist multiple splice variants of EVI1 whose 
functions are presently unclear (Alzuherri et al., 2006; Jazaeri et al., 2010; Vinatzer et al., 
2003). In particular, the MDS1/EVI1 is a read-through splice form which contains a novel 
PR (PRD1-BF1-RIZ homology) domain; its functionality is unclear and is suggested to be 
context or cell type dependent (either eliciting functionality similar or antagonistic to EVI1 
(Vinatzer et al., 2003). Structurally, EVI1 contains 2 zinc finger domains, an intervening 
region required for transformation, and a repressor domain necessary for binding to 
CtBP1/HDAC (Nanjundan et al., 2007).  
In ovarian cancer, the first report of altered EVI1 expression in ovarian carcinoma cells 
demonstrated up to a 40-fold increase in its mRNA levels via RNAse protection assay 
compared to the normal ovary; these initial findings implicate a novel role for EVI1 in 
solid tumor carcinogenesis (Brooks et al., 1996). A decade later, increased EVI1 levels in 
advanced stage ovarian cancers supported these initial findings via oligonucleotide arrays 
profiling and validation via qPCR analysis (Sunde et al., 2006). The same researchers also 
found that the EVI1 gene locus was amplified in 43% of the tumors with a significant 
correlation between gene copy and EVI1 gene expression levels (Sunde et al., 2006). They 
also reported that EVI1 inhibited TGF signaling in normal immortalized ovarian 
epithelial cells (Sunde et al., 2006). Our research has also uncovered increased copy 
number at the EVI1 locus in advanced stage serous epithelial ovarian carcinomas via 
aCGH analysis (Nanjundan et al., 2007). We found that EVI1 DNA copy number increases 
were associated with at least a 5-fold increase in RNA transcript levels in the majority of 
advanced ovarian cancers (Nanjundan et al., 2007). More recent whole genome aCGH 
analysis of stage III ovarian serous carcinomas also identified a gain at 3q26.2 with their 
gene expression analysis demonstrating elevated EVI1 expression (Osterberg et al., 2009). 
Protein level determination via western blotting analysis showed a corresponding 
increase in MDS1/EVI1 and EVI1 expression in ovarian cancers and multiple ovarian 
cancer cell lines (Nanjundan et al., 2007). Interestingly, functional studies by transient 
transfection into normal immortalized epithelial cells demonstrated that EVI1 and 
MDS1/EVI1 increased cell proliferation, migration, and decreased TGF-mediated 
plasminogen activator inhibitor-1 (PAI-1) promoter activity (Nanjundan et al., 2007). In 
yet another recent study, highest expression of EVI1 and a splice variant, Del324 (EVI1s), 
was observed in ovarian cancer specimens with a constant ratio between the two splice 
www.intechopen.com
 
Ovarian Cancer – Basic Science Perspective 
 
128 
variants across all specimens assessed (Jazaeri et al., 2010). However, their analysis did 
not identify an altered expression protein pattern between serous ovarian cancers and 
fallopian tube fimbria or benign neoplasms (Jazaeri et al., 2010). In support of our 
functional studies in OVCAR8 cells (Nanjundan et al., 2007), when EVI1 was expressed 
exogenously in this ovarian carcinoma cell line (which harbors a deletion at the EVI1 
locus), there was no altered proliferation (Jazaeri et al., 2010). Furthermore, with 
knockdown of specific EVI1 forms (via siRNA and shRNA) in ovarian cancer cells, there 
was no alteration in functionality (Jazaeri et al., 2010). Although their data do not support 
a role for EVI1 in ovarian cancer cell proliferation (Jazaeri et al., 2010), further 
investigations are warranted to determine the functional relevance of disrupted TGF 
signaling via EVI1 in ovarian cancer. 
5.1 Epigenetic aberrations, EVI1, and ovarian cancer 
Epigenetic modifications refers to changes in gene expression as a result of DNA 
methylation, histone modification, nucleosome repositioning, and post-transcriptional gene 
regulation by micro-RNAs (Balch et al., 2009). DNA methyltransferases are involved in 
adding methyl groups to the cytosine-5 position within CpG dinucleotides (Balch et al., 
2009). CpG dense regions, however, are normally unmethylated in normal specimens (Balch 
et al., 2009). Histone modifications are extensive and can regulate transcription in an open or 
closed conformation on the chromatin structure (Balch et al., 2009). These regions can be 
extensively altered in disease states such as cancer with a general DNA hypomethylation 
status and localized hypermethylation of promoter associated CpG islands in cases of tumor 
suppressor genes (Balch et al., 2009). Further, dysregulation of miRNA expression has been 
also linked to cancer development (Balch et al., 2009). A number of epigenetic aberrations 
are well noted in ovarian cancer (Balch et al., 2009).  
Based on homology to proteins with PR domains, MDS1/EVI1 (which contains such a 
domain) has the potential to elicit protein methyltransferase activity (Vinatzer et al., 2003; 
Vinatzer et al., 2001). However, we did not detect any such activity associated with 
MDS1/EVI1 via in vitro methyltransferase activity assays using free histones as substrate 
(Nanjundan et al., 2007). There was some weak associated activity which we suggested to be 
due to co-immunoprecipitating molecules, possibly SWI/SNF components or proteins 
associated with methyltransferase activity (Nanjundan et al., 2007). Indeed, EVI1 has 
recently been shown to physically interact with molecules which have such activities 
(Cattaneo & Nucifora, 2008; Lugthart et al., 2011; Pradhan et al., 2011; Senyuk et al., 2011; 
Spensberger & Delwel, 2008).  
Indeed, links between DNA hypermethylation and EVI1 are observed in AML (Lugthart et 
al., 2011); further, EVI1 physically interacts with DNA methyltransferase 3A/3B 
(DNMT3A/3B) (Senyuk et al., 2011). Thus, EVI1 is likely involved in promoter DNA 
methylation in leukemia and possibly in other solid tumors such as ovarian cancers. EVI1 
regulates the expression of microRNA-124 which is involved in regulation of differentiation 
and cycling of hematopoietic cells (De Weer et al., 2011; Dickstein et al., 2010). This was 
demonstrated to occur via methylation of CpG dinucleotides upstream of the miRNA 
leading to its repression and hence, increased expression of genes involved in cell division 
such as Bmi1 and cyclin D3 (De Weer et al., 2011; Dickstein et al., 2010). Through its 
interaction with DNMT3, the EVI1 complex binds to regulatory regions of the miRNA to 
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regulate its expression (De Weer et al., 2011; Dickstein et al., 2010). Of further interest is the 
recent identification of the physical interaction between EVI1 and SIRT1, a histone 
deacetylase which is itself a direct target of EVI1. Interaction between SIRT1 and EVI1 leads 
to EVI1 degradation (Pradhan et al., 2011). SIRT1 is increased in AML patient samples 
where EVI1 is elevated (Pradhan et al., 2011). In addition, EVI1 interacts directly with 
SUV39H1 and G9a, both histone methyltransferases, which elicit methyltransferase activities 
and enhance the repressive activity of EVI1 (Cattaneo & Nucifora, 2008; Spensberger & 
Delwel, 2008). Thus, the oncogenic activity of EVI1 may be involved in deacetylation and 
methylation events which would lead to altered chromatin structure and, thus, 
transcriptional events.  
6. Novel perspective into the functionality of TGF: Autophagy 
More recently, TGF has been implicated in regulating autophagy (Gajewska et al., 2005; 
Kiyono et al., 2009), a self eating process whereby damaged cellular organelles and other 
cellular material are sequestered within autophagosomes. These double-membrane 
structures eventually fuse with single-membrane lysosomes leading to degradation of the 
inner contents (Huang & Klionsky, 2007; Yang & Klionsky, 2009) (Figure 3). Autophagy is 
activated in response to multiple stresses during cancer progression including nutrient 
starvation, the unfolded protein response (UPR), hypoxia, and cellular treatment with 
cytotoxic chemotherapeutic agents (Huang & Klionsky, 2007; Yang & Klionsky, 2009). It has 
been suggested that autophagy promotes tumorigenic development; thus, it would be an 
ideal target for tumor ablation. Indeed, increased levels of autophagy are observed in tumor 
cells following treatment of cells with chemotherapeutic agents (Kondo et al., 2005; Kondo & 
Kondo, 2006). 
The isolation membrane of the autophagosome arises due to complex formation between 
beclin-1 and hVps34 (Geng & Klionsky, 2008; Klionsky, 2005; Wang & Klionsky, 2003; 
Yorimitsu & Klionsky, 2005). The membrane elongates via activation of ubiquitin-like 
conjugation system. ATG12 is activated by ATG7 which is then transferred to ATG10 and 
finally covalently attached to ATG5 (Geng & Klionsky, 2008). The ATG12-ATG5 conjugate 
localizes to autophagosome precursors and dissociates prior to or following completion of 
formation of the autophagic vacuole. Another ubiquitin-like modification system involving 
LC3 (microtubule associated protein 1 light chain 3) completes autophagosome formation 
(Geng & Klionsky, 2008). The cytosolic precursor of LC3 (LC3-I) becomes cleaved at its C-
terminus by ATG4 and is conjugated to phosphatidylethanolamine (PE) to generate the 
membrane bound LC3-II form; this process requires ATG7 and ATG3 activities (Geng & 
Klionsky, 2008; Klionsky, 2005; Wang & Klionsky, 2003; Yorimitsu & Klionsky, 2005). LC3-II 
is specifically targeted to ATG12-ATG5 associated autophagosomal precursor membranes. 
Following fusion of autophagosomes with lysosomes, LC3-II becomes delipidated and 
returns to the cytosolic pool to be recycled (Geng & Klionsky, 2008; Klionsky, 2005; Wang & 
Klionsky, 2003; Yorimitsu & Klionsky, 2005). 
The initial finding that TGF induces autophagy was observed in bovine mammary 
epithelial BME-UV1 cells; both LC3 and beclin-1 expression were induced following TGF1 
treatment leading to cell death (Gajewska et al., 2005). Following reports support this 
finding in a number of cell lines including hepatocellular and breast carcinoma cell lines 
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(Kiyono et al., 2009). TGF was noted to induce autophagosome formation with a 
corresponding conversion of LC3-I to LC3-II and increased expression of autophagic 
markers including beclin-1, ATG5, ATG7, and DAPK (Kiyono et al., 2009). In addition, 
knockdown of SMADs and other targets in the non-canonical SMAD pathways decreased 
TGF mediated autophagy (Kiyono et al., 2009). Autophagy induction led to induction of 
BIM and BMF (proapoptotic markers) which occurred prior to initiation of apoptosis 
(Kiyono et al., 2009).  
 
 
 
 
Fig. 3. Activation of the TGF signaling pathway induces autophagy. TGF can induce 
autophagosome formation in cancer cell lines via enhanced expression of autophagic 
markers (i.e. beclin-1, ATG5, and ATG7) and enhanced conversion of LC3-I to LC3-II.  
Induction of TGF -mediated autophagy occurs prior to apoptosis.  
Supporting reports of TGF-induced autophagy arise from studies of renal epithelial cells 
which is involved in induction of peritubular fibrosis and degeneration of nephrons 
(Koesters et al., 2010). Opposing the concept that TGF leads to autophagic mediated cell 
death, TGF was reported to protect mesangial cells from apoptosis as a protective 
mechanism for survival during serum starvation via a TAK1 and AKT dependent pathway 
(Ding et al., 2010).  
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Our recent work has shown that upon exposure to reactive oxygen generating conditions 
(i.e. arsenic trioxide (As2O3) which is used to treat patients with acute promyelocytic 
leukemia (APL)), SnoN protein levels increase which coincides with induction of autophagy 
in a beclin-1 independent manner (Smith et al., 2010). Other TGF signaling mediators were 
examined and As2O3 was found to reduce the protein expression of EVI1, TAK1, SMAD2/3, 
and TGFRII while increasing SnoN (Smith et al., 2010). Knockdown of SnoN via siRNA 
markedly reduced autophagy with a corresponding increase in apoptosis (Smith et al., 
2010). Thus, disruption of induction of autophagy may be a novel therapeutic strategy to re-
establish or increase sensitivity to therapeutic agents. 
7. Targeting the TGFsignaling pathway for therapy 
Strategies need to be carefully designed for successful treatment of ovarian cancer patients 
via inhibition of TGF signaling pathway due to the apparent bifunctionality of TGF 
signaling. In particular, TGF levels, TGF receptor expression, and tumor 
stage/progression need to be assessed. There are in essence three major groups of TGF 
signaling therapeutics: (1) ligand traps including monoclonal TGF neutralizing antibodies 
and soluble TGFRI/RII; (2) antisense molecule mediated silencing strategies for targeting 
TGF ligands; and (3) small molecule inhibitors targeting TGFRI/RII and downstream 
mediators (Chou et al., 2010; Iyer et al., 2005; Korpal & Kang, 2010; Nagaraj & Datta, 2010).  
Neutralizing antibodies are designed to disrupt the interactions between TGF ligands and 
their cell-surface receptors (Chou et al., 2010). Some of these include 2G7 and 1D11 
monoclonal antibodies which hinder the activity of all three TGF ligands to reduce tumor 
growth and metastasis (Chou et al., 2010). GC1008 is yet another neutralizing antibody 
which entered a Phase I/II clinical trial for advanced malignant melanoma and renal cell 
carcinoma patients (Chou et al., 2010). Soluble ligand traps include soluble TGFRII/III 
which hinder TGF interaction with its cognate cell surface receptors leading to inhibition of 
tumor growth and metastasis in athymic murine models (Chou et al., 2010). Antisense 
oligonucleotides are yet another route to block TGF signaling, specifically against TGF1 
gene expression which reduced tumor survival and metastasis in mouse models (Chou et 
al., 2010). In particular, AP12008, an antisense molecule which targets TGF2, effectively 
targets pancreatic and melanoma cell lines; it entered a Phase IIb clinical trial for patients 
with high grade gliomas with successful outcomes (Chou et al., 2010). However, the 
effectiveness of these large molecule inhibitors has limitations including adequately 
targeting a solid tumor due to physical barriers (Chou et al., 2010). Thus, small molecule 
inhibitors may be more effective and have been developed to initially target TGFRI kinase 
activity with specificity (i.e. SB0431542, SD-208, LY580276, etc.). These act as competitive 
inhibitors of the ATP binding site of TGFRI kinase (Chou et al., 2010). In addition, there 
now exists a dual inhibitor of TGFRI and TGFRII (LY2109761) which hinders metastatic 
process effectively (Chou et al., 2010). Other strategies that are being developed include 
small molecule inhibitors to directly inhibit SMAD-specific pathways as opposed to the non-
canonical pathways (Chou et al., 2010).  
In addition to the above targeting strategies, epigenetic therapy may also be another 
valuable therapeutic strategy for ovarian cancers with respect to targeting TGF 
transcriptional co-regulators such as EVI1. This strategy could potentially alter the 
epigenetic status leading to restoration of the expression of tumor suppressor genes with a 
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corresponding reduction in the expression of genes involved in mestastasis. For example, 
ADAM19, FBXO32, and RunX1T1 (tumor suppressors) are reduced in ovarian cancers but 
are normally increased in response to TGFthese genes are epigenetically silenced by 
promoter hypermethylation or histone modification (Balch et al., 2009).  
With respect to SnoN/SkiL (Figure 4), based on our results with As2O3 in ovarian carcinoma 
cells, targeting of this TGF transcriptional co-regulator in ovarian cancers may lead to 
increased sensitivity to various chemotherapeutic agents. 
 
 
Fig. 4. Targeting of SnoN/SkiL to increase the sensitivity of ovarian cancer cells to 
chemotherapeutics. SnoN/SkiL levels increase following As2O3 treatment leading to 
induction of autophagy and increased resistance to the agent. Targeting of SnoN/SkiL with 
specific inhibitors may be a strategy to improve the sensitivity of the chemotherapeutic 
agents in ovarian cancer patients.   
8. Conclusion  
Although significant progress has been made in improving our understanding of the 
TGFsignalling pathway, there remain numerous areas for further investigation to improve 
our understanding of the regulation of the TGFpathway. Thus, future research could 
possibly lead to development of novel and improved strategies for treatment of ovarian 
cancer patients.  
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